Sunshine Biopharma, Inc. (NASDAQ:SBFMW) Sees Significant Decline in Short Interest

Sunshine Biopharma, Inc. (NASDAQ:SBFMW) saw a significant decrease in short interest in the month of May. As of May 29th, there was short interest totaling 1,317 shares, a decrease of 76.6% from the May 14th total of 5,626 shares. Based on an average daily volume of 26,884 shares, the short-interest ratio is currently 0.0 days.

Sunshine Biopharma Trading Down 15.4%

Shares of NASDAQ SBFMW traded down $0.01 during trading on Friday, reaching $0.03. The company had a trading volume of 29,456 shares, compared to its average volume of 11,266. Sunshine Biopharma has a 12-month low of $0.03 and a 12-month high of $0.65. The business’s 50-day moving average is $0.11 and its 200 day moving average is $0.15.

About Sunshine Biopharma

Sunshine Biopharma is a development-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics for oncology and antiviral applications. The company’s research activities encompass the design, synthesis and preclinical evaluation of compounds that inhibit key pathways involved in cell proliferation and viral replication.

Among its lead programs, Sunshine Biopharma is advancing Adva-27a, a topoisomerase II inhibitor licensed from the National Research Council of Canada, which is undergoing preclinical studies for potential use in breast and ovarian cancers.